SREBF1 and glioblastoma: This is supported by in vivo studies employing EGFRvIII-bearing glioblastoma cells showing the high dependency of the cells on SREBP1 for survival and demonstrating that inhibition of SREBP1 and FASN, respectively, promotes massive tumor cell death in cancer cells bearing activated EGFR signaling [71].